Glenmark Pharma was founded by Gracias Saldanha in 1977. It is ranked 14th in Indian pharmaceutical market as of 2019. It sells generics and APIs to 80+ markets.
Product Segments
- Formulations
- Branded Generics
- Generics
- Specialty
- OTC (Over the Counter)
- API
Revenue Across Geographies
*MEA - Middle East & Africa
*LATAM - Latin America
*ARCIS - Asia, Russia and other Commonwealth of Independent States
Indian Markets
It is ranked 14th in Indian pharmaceutical market.
Ranked 2nd in Dermatology, 4th in Respiratory and 6th in the Cardiac segments.
VWash, Candid DP, Scalpe+ are flagship OTC products.
North American Markets
It is 15th largest generics manufacturer by prescriptions in USA.
145 ANDAs approved, 50+ pending approval as of December 2019.
It is the leading company in generics dermatology segment.
European & Latin American Markets
Key markets include UK, Germany, Poland, Brazil & Mexico.
It launched Momate AZ, Glemont and Nebzmart in Latin American market.
Russia & CIS Markets
Glenmark ranks 4th amongst the expectorant segment.
It ranks 7th in overall dermatology segment.
Nourkrin Hair is a recently launched flagship product.
Glenmark Life Sciences (API Business)
It is run under subsidiary Glenmark Life Sciences.
Some of the leading molecules are Atovaquone, Lercanidipine, Aprepitant, Amiodarone, Olmesartan, Perindopril and Etoricoxib.
Comments
Post a Comment